The 2025 move to Schedule III reclassifies cannabis as a medicinal substance, ending the 280E tax penalty and boosting industry cash flow. While facilitating pharmaceutical research and institutional investment, it maintains federal prohibition for recreational markets.
THC and CBD are primary cannabinoids that interface with the endocannabinoid system to regulate homeostasis. THC provides euphoria and manages nausea or pain, while CBD offers non-intoxicating benefits for epilepsy, anxiety, and inflammation through complex pathways.
Explore the complex world of cannabis in this comprehensive 2026 guide. From botanical debates regarding Sativa and Indica to research on THC, CBD, and the “entourage effect,” we detail the plant’s therapeutic potential and public health risks. Stay updated on global legalization trends, including Germany’s reforms and U.S. rescheduling, to understand the future of this pharmacological revolution.